Objective While guidelines advocate renin-angiotensin system inhibitors (RASi) for renoprotection in lupus nephritis (LN), ...

Objective Hydroxychloroquine (HCQ) is a cornerstone therapy for SLE, reducing flares, organ damage and mortality. However, ...

Objective SLE is a heterogeneous systemic autoimmune disease with diverse clinical manifestations. We aimed to identify ...

For more than a century, certain bacterial infections that breach skin or mucosal barriers have been known to act as triggers of autoimmune syndromes, including rheumatic fever and post-streptococcal ...

Low disease activity and remission are recognized as important goals in the treatment of patients with lupus and as valuable outcomes in epidemiological research and in clinical trials. The former is ...

Zucker School of Medicine at Hofstra/Northwell, New York, USA In summary, robust B-cell depletion with obinutuzumab was responsible for the attainment of significant effect sizes observed in NOBILITY ...

Objective Disease severity in SLE is an important concept related to disease activity, treatment burden and prognosis. We set out to evaluate if high disease activity status (HDAS), based on ever ...

Objective Belimumab has well-established efficacy in improving overall SLE disease activity and preventing flares and organ ...

Objective Psychological comorbidities are common in adolescents with SLE. Incorporating structured mental-health screening ...

Anaemia is a frequent and clinically relevant complication of systemic lupus erythematosus (SLE), particularly in patients ...

Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis. Phase II studies have shown promising results, although long-term data are ...

Objective Strategies to Embrace Living with Lupus Fearlessly (SELF) is an online self-management education programme for people with SLE. This mixed-methods study examines SELF’s impact on ...